Sei Investments Co. reduced its stake in C.R. Bard, Inc. (NYSE:BCR) by 11.5% during the second quarter, Holdings Channel reports. The institutional investor owned 33,075 shares of the medical instruments supplier’s stock after selling 4,284 shares during the period. Sei Investments Co.’s holdings in C.R. Bard were worth $10,456,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. SRS Capital Advisors Inc. increased its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares in the last quarter. Creative Planning increased its stake in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares in the last quarter. Blair William & Co. IL increased its stake in C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after buying an additional 30 shares in the last quarter. First Merchants Corp increased its stake in C.R. Bard by 0.6% in the second quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after buying an additional 32 shares in the last quarter. Finally, Pennsylvania Trust Co increased its stake in C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares in the last quarter. 85.32% of the stock is owned by institutional investors and hedge funds.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at 319.13 on Friday. The firm has a 50-day moving average of $318.89 and a 200-day moving average of $282.81. The stock has a market cap of $23.19 billion, a PE ratio of 41.90 and a beta of 0.59. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $323.27.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. During the same quarter last year, the business posted $2.54 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities research analysts expect that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were issued a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. C.R. Bard’s payout ratio is 13.67%.
A number of equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a research report on Tuesday, June 13th. BMO Capital Markets cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price objective on the stock. in a research report on Tuesday, April 25th. Morgan Stanley cut shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. BidaskClub cut shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $285.67.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
